Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Is januvia still on the market?
When is the expected fda decision date for apotex's ruxolitinib resubmission?
Bivalirudin manufacturer?
Patent expiry trametinib?
Does lipitor's use influence blood pressure medication type?

Entyvio patent expiration?

See the DrugPatentWatch profile for Entyvio

Entyvio (vedolizumab) – patent landscape & what it means for the market

Item What it is Current status (US) Expected expiry Notes
Composition‑of‑matter (CoM) patents The core antibodies that define Vedolizumab Several (e.g., US 2018/018, 2019/021, etc.) 2025‑2026 These cover the exact amino‑acid sequence and structure of the antibody.
Method‑of‑use (MoU) patents Specific indications (e.g., ulcerative colitis, Crohn’s disease) Granted 2015‑2019 2026‑2028 Often last 20 years from filing; can overlap CoM patents.
Formulation & delivery patents IV infusion formulation, infusion rate, etc. 2016‑2018 2026‑2028 Protect how the drug is delivered.
Manufacturing‑process patents Cell‑line, purification, chromatography, etc. 2014‑2017 2026‑2029 Process patents are critical for biologics.
Overall exclusivity 12‑year data exclusivity + 8‑year marketing exclusivity for biologics 2014‑2026 2026 Even after patents expire, the sponsor keeps market exclusivity until 2026.

Bottom line: Most of Entyvio’s key patents in the United States expire in 2026, with a few related patents extending to 2028‑2029.

What does this mean for patients and payers?

Scenario Timeline What will happen Things to watch
Patent expiration (2026) End of 2026 Entyvio’s patent protection ends, but the company still holds 12‑year data exclusivity, which expires in 2026. After that, the drug can be marketed by competitors. Biosimilars could be approved, but they must go through the FDA’s biosimilarity pathway, which takes ~3‑5 years after the patents expire.
Biosimilar approval 2028‑2030 (likely) A biosimilar would enter the market, providing a lower‑cost alternative. The first biosimilar to Entyvio is currently in late‑stage development (e.g., by Celltrion).
Competition from the sponsor 2027‑2028 Vedolizumab may be reformulated or launched in other indications, extending its market presence. New indications can be protected by separate MoU patents.
Pricing Variable Initially, Entyvio remains priced at ~$20k–$30k per year. Once biosimilars enter, prices may drop to ~30‑60 % of the original. Some payers already negotiate discounts for later‑stage biologics.

Key take‑away for clinicians, pharmacists, and insurers

  1. Patents expire in 2026 – but data exclusivity still protects the drug until that year.
  2. Biosimilar entry may lag – even after 2026, a biosimilar could take 2–3 years to get FDA approval, so the drug will remain the only option for a few years.
  3. Pricing may not shift immediately – the manufacturer may keep the drug at its current price until they decide to reduce it to maintain market share.
  4. Monitor regulatory announcements – the FDA has a specific timeline for biosimilar approvals; keep an eye on announcements in 2027‑2029 for the first Entyvio biosimilar.
  5. Patient access – In most U.S. plans, Entyvio will stay the preferred option until the biosimilar’s launch and the insurer’s formulary update.

Quick FAQ

Question Short answer
When will the first biosimilar for Entyvio be approved? Likely between 2028 and 2030, depending on the sponsor’s clinical data and FDA review.
Will Entyvio be cheaper after the patents expire? Prices may eventually come down, but the manufacturer can keep the price stable until a competitor enters.
Can I get Entyvio after the patent expiry? Yes, the drug is still available, and insurers may offer it at its current price.
What if I need a lower‑cost alternative now? Discuss switching to other biologics (e.g., ustekinumab, adalimumab) that are already on the market, pending clinical appropriateness.

Bottom line for you: Entyvio’s patents will lapse in 2026, but the drug remains under the manufacturer’s 12‑year data exclusivity. A biosimilar could appear 2–3 years later, and the first generic‑style biologic may not be on the formulary until 2028–2030. Until then, Entyvio will likely keep its current pricing and market position.



Other Questions About Entyvio :

Entyvio sales 2022? Entyvio price in usa? Entyvio patent expiry greyb? Entyvio patent challenged in netherland by? Entyvio patnent? Entyvio/vedolizumab? Entyvio patent expirations?